ESR1 and breast carcinoma: Varying results have been reported, but based on improved invasive disease–free survival in the monarchE trial, abemaciclib was the first CDK4/6 inhibitor to be approved as an adjuvant therapy in women with high-risk, nonmetastatic, ER+ breast cancer with a high Ki67 score (8–10).